Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

India mulls legal action against US think tank's 'smear' campaign

This article was originally published in Scrip

Executive Summary

Even as India's Prime Minister Narendra Modi is set to begin his high profile five-day visit to the US showcasing the country's best side to top global investors, senior government officials were engaged in a major fire-fighting exercise over allegations against the quality of medicines from India.

You may also be interested in...



Obituary: Indian Generics Industry Torchbearer Dilip Shah

Indian industry veteran and secretary general of the Indian Pharmaceutical Alliance, Dilip Shah, has died aged 77. Shah, a former commercial director of Pfizer in India, played a pivotal role in ensuring that the Indian generic industry's voice was heard.

Asia Deal Watch: Hansoh Teams Up With OliX On SIRNA Therapies

Among other Asia deals, Takeda adds to pair of recent gene therapy tie-ups with a CNS-focused cell therapy partnership with Immusoft; earlier it licensed ex-US rights to JCR’s Hunter syndrome drug.

Deciphering Molnupiravir’s India Trial Discontinuation In Moderate COVID-19

Two Indian firms want to terminate specific Phase III trials for molnupiravir, the Merck/ Ridgeback Biotherapeutics’ antiviral in the spotlight as a treatment for mild-to-moderate COVID-19. Should much be read into these plans or is it merely an “administrative closure” that is being sought?

Topics

Related Companies

UsernamePublicRestriction

Register

SC026471

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel